Temporal changes of cardiac acoustic biomarkers and cardiac function in acute decompensated heart failure.

Acoustic cardiography Cardiac acoustic biomarkers Heart failure Heart sound

Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
10 2021
Historique:
revised: 26 05 2021
received: 11 02 2021
accepted: 15 06 2021
pubmed: 30 6 2021
medline: 30 10 2021
entrez: 29 6 2021
Statut: ppublish

Résumé

Relationships between cardiac acoustic biomarkers (CABs) measured by acoustic cardiography and clinical outcomes have been reported in heart failure (HF) patients. However, no studies have investigated the temporal change of CABs and the corresponding changes in HF status. The purpose of this study was to assess whether the temporal changes of CABs in patients with acute decompensated heart failure (ADHF) reflect changes in cardiac function and status. Sixty ADHF patients were enrolled prospectively. CABs and echocardiography data were collected at admission, before discharge, and at the first clinic visit. CABs included electromechanical activation time (EMAT); the time interval from Q wave onset on electrocardiography to the first heart sound (S1), QoS2; the time interval from Q wave onset on electrocardiography to the second heart sound (S2); and third heart sound (S3) and fourth heart sound (S4) intensities, defined as the peak-to-peak amplitudes of S3 and S4. EMATc (EMAT/RR) (P = 0.001), S3 intensity (P < 0.001), and S4 intensity (P < 0.001) were significantly decreased, and QoS2 (P = 0.005) was significantly increased from admission to discharge. The change in S3 intensity was significantly correlated with that of E/A (ρ = 0.571, P < 0.001), and the extended QoS2 was also significantly correlated with the increase in the stroke volume index (ρ = 0.383, P = 0.004). Some CABs in ADHF patients changed significantly in the normal direction throughout the treatment course and could be useful biomarkers in ADHF management.

Identifiants

pubmed: 34184415
doi: 10.1002/ehf2.13492
pmc: PMC8497215
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4037-4047

Informations de copyright

© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Clin Cardiol. 2011 Jun;34(6):384-8
pubmed: 21538386
Int J Clin Pract. 2015 Aug;69(8):820-8
pubmed: 25521285
Int J Cardiol. 2013 Aug 10;167(3):681-6
pubmed: 22456263
Int J Cardiol. 2014 Apr 1;172(3):548-60
pubmed: 24529949
Arch Intern Med. 2006 Mar 27;166(6):617-22
pubmed: 16567599
J Am Soc Echocardiogr. 2005 Dec;18(12):1440-63
pubmed: 16376782
J Clin Invest. 1984 May;73(5):1400-7
pubmed: 6715543
J Card Fail. 2020 Feb;26(2):151-159
pubmed: 31634574
J Card Fail. 2007 Feb;13(1):18-24
pubmed: 17338999
ESC Heart Fail. 2019 Apr;6(2):308-318
pubmed: 30632306
Circulation. 1977 Aug;56(2):146-58
pubmed: 872305
Am Heart J. 2017 Jul;189:193-199
pubmed: 28625377
Circulation. 1970 Sep;42(3):455-62
pubmed: 5451230
Am Heart J. 1961 Sep;62:367-78
pubmed: 13784135
Ann Noninvasive Electrocardiol. 2020 Mar;25(2):e12717
pubmed: 31617647
Circ Res. 2013 Aug 30;113(6):646-59
pubmed: 23989710
J Card Fail. 2020 Feb;26(2):142-150
pubmed: 31568829
Ann Noninvasive Electrocardiol. 2007 Apr;12(2):89-97
pubmed: 17593176
Int J Cardiol. 2004 Nov;97(2):183-6
pubmed: 15458681
ESC Heart Fail. 2021 Oct;8(5):4037-4047
pubmed: 34184415
JACC Heart Fail. 2017 Mar;5(3):216-225
pubmed: 28254128
J Appl Physiol. 1964 Mar;19:279-83
pubmed: 14155296

Auteurs

Jun Shitara (J)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.

Takatoshi Kasai (T)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Sleep and Sleep Disordered Breathing Center, Juntendo University Hospital, Tokyo, Japan.

Nobutaka Murata (N)

Healthcare R&D Center, Asahi Kasei Corporation, Tokyo, Japan.

Nobuhide Yamakawa (N)

Healthcare R&D Center, Asahi Kasei Corporation, Tokyo, Japan.

Shoichiro Yatsu (S)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.

Azusa Murata (A)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.

Hiroki Matsumoto (H)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Takao Kato (T)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.

Shoko Suda (S)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.

Yuya Matsue (Y)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Ryo Naito (R)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Masaru Hiki (M)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.

Hiroyuki Daida (H)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH